Intellia Therapeutics Inc (NTLA) — Cash Flow-to-Debt Ratio
Intellia Therapeutics Inc (NTLA) has a Cash Flow-to-Debt Ratio of -0.41x as of December 2025, meaning its operating cash flow of $-69.28 Million could theoretically repay 0% of its total liabilities ($170.73 Million) in one year. See cash generation quality of Intellia Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Intellia Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Intellia Therapeutics Inc across 12 annual periods. Also explore NTLA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Intellia Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Intellia Therapeutics Inc. For market capitalisation and broader financial context, see market cap of Intellia Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.04x | $-348.88 Million | $170.73 Million | ▼ -86.9% |
| 2024 | -1.09x | $-348.88 Million | $319.06 Million | ▲ +30.4% |
| 2023 | -1.57x | $-394.09 Million | $250.81 Million | ▼ -34.1% |
| 2022 | -1.17x | $-333.29 Million | $284.53 Million | ▼ -32.3% |
| 2021 | -0.89x | $-225.03 Million | $254.22 Million | ▼ -164.7% |
| 2020 | -0.33x | $-49.91 Million | $149.25 Million | ▲ +79.1% |
| 2019 | -1.60x | $-103.24 Million | $64.40 Million | ▼ -81.6% |
| 2018 | -0.88x | $-61.26 Million | $69.39 Million | ▼ -2.3% |
| 2017 | -0.86x | $-65.28 Million | $75.64 Million | ▼ -313.0% |
| 2016 | 0.41x | $36.11 Million | $89.13 Million | ▲ +439.7% |
| 2015 | -0.12x | $-1.76 Million | $14.78 Million | ▲ +89.3% |
| 2014 | -1.11x | $-3.48 Million | $3.13 Million | — |